A 12-Month Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Patients With Partial Lipodystrophy

Protocol No
ENDO-AMRYT-APG-20
Staff Member
Bradley R Javorsky
Phase
III
Summary

This project is being done to see whether a medication called metreleptin, also known as the study medication/treatment, is safe and works in patients with familial partial lipodystrophy (FPLD).
Objective
Daily Subcutaneous Metreleptin Treatment in Patients With FPLD
Study Sites
Froedtert Hospital
Status
OPEN TO ACCRUAL
Categories
Diabetes and Endocrinology
ClinicalTrials.gov
https://www.clinicaltrials.gov/study/NCT05164341